Tox Cards: Novel Synthetic Opioids

Author: Kristin E. Fontes, MD (Emergency Physician, Santa Barbara Cottage Hospital and Goleta Valley Cottage Hospital) // Edited by: Cynthia Santos, MD (Assistant Professor Emergency Medicine, Toxicology), Alex Koyfman, MD (@EMHighAK, EM Attending Physician, UTSW / Parkland Memorial Hospital), and Brit Long, MD (@long_brit, EM Attending Physician, San Antonio Military Medical Center)

Case presentation:

An obtunded 30-year-old man is brought to the emergency department by ambulance. He was picked up from a local hotel room where paramedics noticed various drug paraphernalia including needles, syringes, and plastic bags containing a white powdery substance. They reported pinpoint pupils and an initial respiratory rate of 5. He was given 2 mg of intramuscular naloxone twice prior to transport, and his breathing improved. After about 5 minutes, however, he again became obtunded. He is unable to provide any history on arrival to the ED.

Initial vital signs are: T 37C, HR 56, BP 100/70, RR 10, SpO2 88% (on 100% supplemental O2 via facemask)

On examination, the patient is pale and poorly responsive. He withdraws to deep sternal rub. He is bradypneic and has sonorous respirations. There are visible needle track marks predominantly over his left arm. He has no external signs of trauma.

The patient’s chart documents multiple previous ED visits involving heroin overdoses. Despite responding to 1 or 2 doses of intravenous naloxone during previous visits, you currently have to give repeat doses (0.4-1 mg increments) every 5-10 minutes due to recurrent respiratory depression. After multiple rounds of this, you start a continuous infusion of naloxone and admit him to the intensive care unit for continued management.


  • In what ways do novel synthetic opioids contribute to drug overdose mortality rates in the United States?
  • What is the relative potency of fentanyl and its derivatives?
  • How should naloxone be administered, and how should health care personnel protect themselves?


  • Novel synthetic opioids (NSOs) include fentanyl derivatives and newly emerging non-fentanyl compounds, often referred to as “designer opioids.” Together with illicitly produced fentanyl, these drugs have caused a recent spike in overdose deaths, whereas deaths from prescription opioids are stabilizing.[1-3]
  • The most recent CDC data demonstrate that during 2014-2015, death rates involving synthetic opioids (other than methadone) increased in both genders and all racial/ethnic groups. While mortality from heroin and semi-synthetic opioids increased as well (20.6% and 2.6%, respectively), the greatest rise was noted with synthetic opioids (72.2%).[2]
  • Most fentanyl-associated deaths are due to illicitly manufactured fentanyl, rather than prescription drug diversion.[3]
  • Whereas synthetic opioids can also include less potent opioids like loperamide, diphenoxylate, and methadone, the focus of this post is on fentanyl and its derivatives.
  • Fentanyl and its derivatives are highly lipophilic and thus rapidly distribute into the central nervous system, which leads to their high potency, rapid onset, and short duration of action; they act primarily as mu-opioid receptor agonists.[4]


Table 1. Relative potency, duration of action, and states reporting mortality from fentanyl and select novel synthetic opioids. [3-5]

  • *The pharmacokinetics of these novel drugs are not yet fully described in the literature, and these agents are not intended for human use. Carfentanil is approved for veterinary use for sedation of large animals.
  • †This list may not be complete, as the spread of novel synthetic opioids is growing faster than published literature on this topic.
  • Other novel synthetic opioids that have been reported include: 4-Fluorobutyrylfentanyl, Furanylfentanyl, Ocfentanil, AH-7921, and MT-45.[5]
  • Fentanyl and its derivatives are commonly found as substitutes/adulterants in other preparations.


Considerations regarding counterfeit pill production:

  • Fentanyl and derivatives are relatively inexpensive, influencing distributors and dealers to choose these over heroin as substitutes/adulterants.
  • Users may be unaware that they are purchasing counterfeit pills, which are often identical in appearance to legally prepared pills.
  • Inconsistent synthesis methods lead to varying drug concentrations in individual pills.


Considerations for healthcare providers due to relative high potency of synthetic opioids:

  • Toxicity from fentanyl and derivatives may require very high doses of naloxone for reversal.
  • Dermal or inhalational exposure may lead to symptom development in first responders; appropriate personal protective equipment must be used.


Naloxone tips when treating fentanyl and novel synthetic opioid exposures:

  • High doses of naloxone may be needed for potent synthetic opioids so quickly escalate naloxone dosing if there is no response. (see Keep in mind patients may require doses of naloxone higher than doses typically needed with other types of opiates (e.g. morphine, codeine), semi-synthetic opioids (e.g. hydromorphone, heroin), and synthetic opioids (e.g. methadone).
  • Some recommend to forgo the initial low starting dose and start with 2 mg of naloxone if the use of fentanyl and novel synthetic opioids are suspected.[3]
  • Retrospective chart review of fentanyl overdoses in Chicago in 2005-2006 reported a mean dose of 3.36 milligrams IV required for rescue (no withdrawal symptoms reported); dose range was 0.4-12 mg.[6] During fentanyl overdose outbreaks, patients have required up to 14 mg of naloxone to reverse CNS and respiratory depression.[7]


Protective Personal Equipment:

  • There have been multiple reports of nurses and first responders becoming symptomatic and requiring Naloxone after dermal and inhalational exposure from exposure of the powdered form of fentanyl or fentanyl derivatives.[7,8]
  • Fentanyl and novel synthetic opioids in the white powder form may put first responders at risk through inhalation of airborne particulate, contact via mucous membranes or possibly through skin contact. Exposure to carfentanil in particular can be risky for first responders since as little as a few grains of salt can result in respiratory depression.[7]
  • If the presence of highly potent synthetic opioids are suspected, health care personal should use nitrile gloves, eye protection, and respiratory protection, with escalation to other types of PPE as situationally indicated.[7,8]


Complications from synthetic opioid toxicity:

  • Rapid death after intravenous fentanyl abuse may be due to chest wall rigidity; mechanism poorly understood but may be related to central dopaminergic activity.[9,10]
  • Pulmonary hemorrhage resulting in hypoxic respiratory failure has been reported after fentanyl and butyrfentanyl abuse; mechanism is unknown.[11]
  • Serotonin syndrome has been reported after fentanyl use in patients concomitantly taking other serotonergic agents.[12]


Key Points:

  • Potent synthetic opioids like Fentanyl and novel synthetic opioids (especially carfentanil) are associated with recent increased mortality from opioid abuse; users are often unaware of what they are consuming.
  • Higher doses (e.g. exceeding 10 mg) of naloxone may be required for rescue from these potent synthetic opioids.
  • Health care personal should use nitrile gloves, eye protection, and respiratory protection if there is high suspicion of the powdered form of these potent synthetic opioids, with escalation to other types of PPE as situationally indicated.



  1. DEA issues carfentanil warning to police and public. (September 22, 2016)
  2. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths – United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016 Dec 30;65(5051):1445-1452.
  3. Prekupec MP, Mansky PA, Baumann MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med 2017 Jun 5 [Epub ahead of print].
  4. Zawilska JB. An expanding world of novel psychoactive substances: opioids. Front Psychiatry 2017 Jun 30;8:110.
  5. Mohr A, Friscia M, Papsun D, Kacinko S, et al. Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC–MS/MS in Postmortem Casework, Journal of Analytical Toxicology 2016. 40(9):709–717.
  6. Schumann H, Erickson T, Thompson TM, Zautcke JL, Denton JS. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin Toxicol 2008 Jul;46(6):501-6.
  7. Lybeck A, Colella R. Synthetic Opioid Overdose: Practical Considerations for Emergency Medical Services. Evidence-based EMS. Available at:
  8. Centers for Disease Control. Fentanyl: Preventing Occupational Exposure to Emergency Responders. Available at:
  9. Burns G, DeRienz RT, Baker DD, Casavant M, Spiller HA. Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse? Clin Toxicol (Phila) 2016 Jun;54(5):420-3.
  10. Coruh B, Tonelli MR, Park DR. Fentanyl-induced chest wall rigidity. Chest 2013 Apr;143(4):1145-1146.
  11. Ruzycki S, Yarema M, Dunham M, Sadrzadeh H, Tremblay A. Intranasal fentanyl intoxication leading to diffuse alveolar hemorrhage. J Med Toxicol 2016 Jun;12(2):185-8.
  12. Gaffney RR, Schreibman IR. Serotonin syndrome in a patient on trazodone and duloxetine who received fentanyl following a percutaneous liver biopsy. Case Rep Gastroenterol 2015 May 6;9(2):132-6.

The post Tox Cards: Novel Synthetic Opioids appeared first on - Emergency Medicine Education.

format changes

Format changes often when a presentation is moved from one computer to another. This is the cause of quite a few nervous starts, anxious half hours and embarrassed deliveries. Make sure everything that the original presentation moves to the podium and to the audience. Format changes apply to everything that can be changed and and The Good Presenter avoids those before getting to the conference stage.

Format changes can be considered under design, programme and image size. Each contains traps for the unwary. There is no foolproof means of avoiding all problems but preparation, arriving early at the event and running through the presentation with time for changes will reduce those stress levels. Format problems can be avoided by considering any opportunity for a computer to change settings.

format changes

An important starting point for a presentation is in its slide size. The “default” size on most recent programmes is now 16:9 but 4:3 on older versions. This image is 16:9, the ones below 4:3. Some versions of Powerpoint to default to “on screen projection” and even this as widescreen is not the same as 16:9, very confusing. Check with the organisers before starting any design; everything will change. If unsure, prepare two presentations, one in 16:9 and one in 4:3.

The commonest format changes are seen with the use of incompatible type. In design, a presenter chooses from the typefaces stored on their computer. These typefaces are drawn from the standard “Office” software but also from downloaded programmes including games and from type specifically downloaded from type foundries. Their weight and position place them in a specific place within a slide and this is saved in the format of the presentation. If this file is then moved to a computer that doesn’t have the same font, a substitution is made. This is seldom equivalent and format changes

format changesformat changes









The most frequently used presentation software is Microsoft Powerpoint. The formatting of a presentation is often very close when transferring presentations across from one computer to another. Problems can occur and it should be noted that backwards compatibility (you having The Most Up To Date version), cross platform compatibility (Mac to PC) and exporting from other software such as Keynote can all lead to issues of a format change.

The best means of avoiding format changes it to present from the computer on which the presentation was constructed. Whilst not ideal, IT support at a conference are now used to presenters arriving and asking to use their own devices. The responsibility here for connection lies solely with the presenter. Purchase your own connector that will take video output from your device and connect to VGA or HDMI. Test run the swap with IT at least twice. If you don’t know what this entails, you probably shouldn’t be attempting this manoeuvre without help.

If your presentation does not involve animation a clean fix is to effectively take screenshots of each slide when constructed and then construct a separate presentation using only these images. For PC, set the presentation in Play mode. Hold Alt-PrntScrn and a copy of the screen is sent to the Clipboard. Annoyingly, there is usually NO mention of this on your screen. Open Paint and Ctrl-V (paste) the result. It may be possible to crop this image. Save as .jpg and then insert this image into the presentation software. For Mac, Ctrl-Shift-4 brings up a cursor. Hold down can then be used with the trackpad to highlight the area of interest. This is saved as a screenshot on the desktop. Edit with Preview if required and insert directly to the programme.


Format changes everything. The Good Presenter is prepared for this. Ensure the correct slide size is set before any slides are constructed. Consider delivering the presentation from your own laptop if there are complex fonts or animations but ensure you have the appropriate connector. If there is any doubt over programmes, compatibility or operating systems use a screenshot and save each slide as a separate image and use this file to present from. Format changes and can catch many unawares.



The post format changes appeared first on p cubed presentations.